
Sign up to save your podcasts
Or


Evie Hobbs, MD, Hematology Oncology Specialist, Providence Cancer Center Oncology and Hematology Care Clinic
CME Credit Available for all Providence Providers
In order to claim CME credit, please click on the following link: https://forms.office.com/r/tuZUy0Zswj or copy & paste into your browser)
Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Planning Committee & Faculty Disclosure:
The Planning Committee have no relevant financial relationships with ineligible companies to disclose. The speaker has indicated relevant financial relationships with ACCME-defined ineligible companies: Avenzo Therapeutics –Principal Investigator (Institution receives funding). The speaker’s presentation will be evidence-based and unbiased.All relevant financial relationships have been mitigated.
Original Date: February 24, 2026
End Date: February 24, 2027
By Providence Oregon Region5
33 ratings
Evie Hobbs, MD, Hematology Oncology Specialist, Providence Cancer Center Oncology and Hematology Care Clinic
CME Credit Available for all Providence Providers
In order to claim CME credit, please click on the following link: https://forms.office.com/r/tuZUy0Zswj or copy & paste into your browser)
Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Planning Committee & Faculty Disclosure:
The Planning Committee have no relevant financial relationships with ineligible companies to disclose. The speaker has indicated relevant financial relationships with ACCME-defined ineligible companies: Avenzo Therapeutics –Principal Investigator (Institution receives funding). The speaker’s presentation will be evidence-based and unbiased.All relevant financial relationships have been mitigated.
Original Date: February 24, 2026
End Date: February 24, 2027